semaglutide
semaglutide: sourced relationships with 1 company · 119 clinical trials tracked · 1 FDA decision.
semaglutide evidence translation
What we can confirm
1 FDA record · 119 tracked trials
What it means
What to watch
Prepared research question
How could semaglutide → NVO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novo Nordisk A/S (NVO) Reported 2020-01-16 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (119)showing 10 most recent
A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity
Primary endpoint: BPI-SF Pain Severity Scale
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Primary endpoint: Number (Incidence) of adverse events (AEs)
A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
Primary endpoint: Feasibility - Recruitment
GLOW (GLP-1 Plus Lifestyle for Overall Wellness)
Primary endpoint: Body Mass Index (BMI) Reduction
An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide
Primary endpoint: Number of treatment emergent adverse events (TEAE)
An Investigation of the Effect of High Dose s.c. Semaglutide on Gastric Emptying in Participants With Obesity
Primary endpoint: AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal
Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
Primary endpoint: Relative change in body weight
A Multicenter, Randomized, Open-Label, Semaglutide Injection-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With Metformin Alone or in Combination With Sulfonylurea/Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Therapy (UNIGUIDE-2)
Primary endpoint: HbA1c
sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
Primary endpoint: Change in Food Noise Questionnaire (FNQ) score
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Primary endpoint: Part A: Number of treatment emergent adverse events (TEAE)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with semaglutide?
semaglutide has dated SEC/FDA relationship records for Novo Nordisk A/S.
How many clinical trials involve semaglutide?
BioSniper tracks 119 clinical trials involving semaglutide.
What is semaglutide's latest FDA decision?
The most recent tracked FDA decision for semaglutide is Approval, dated January 16, 2020.